脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(化學發(fā)光免疫分析法)
CLIA Kit for Phospholipase A2 Group VII (LpPLA2)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- 編號SCA867Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長2h, 40min
- 檢測范圍13.7-10,000pg/mL
- 靈敏度最小可檢測劑量小于等于4.8pg/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 3528 ¥ 5040 ¥ 22680 ¥ 42840 ¥ 352800
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)(加標樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 79-104 | 91 |
EDTA plasma(n=5) | 95-102 | 99 |
heparin plasma(n=5) | 85-105 | 94 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 86-94% | 78-95% | 91-105% | 81-92% |
EDTA plasma(n=5) | 78-92% | 80-95% | 98-105% | 90-104% |
heparin plasma(n=5) | 87-94% | 90-104% | 92-101% | 79-90% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本的準備;
2. 加樣(標準品及樣本)100µL,37°C孵育1小時;
3. 吸棄,加檢測溶液A100μL,37°C孵育1小時;
4. 洗板3次;
5. 加檢測溶液B100µL,37°C孵育30分鐘;
6. 洗板5次;
7. 加底物100µL,37°C孵育10分鐘;
8. 讀數(shù)。
實驗原理
將脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)抗體包被于96孔微孔板中,制成固相載體,向微孔中分別加入標準品或標本,其中的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)抗體,將未結(jié)合的生物素化抗體洗凈后,加入HRP標記的親和素,再次徹底洗滌后加入底物。加入底物后會產(chǎn)生輝光型光信號。發(fā)射光強度和樣品中的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)呈正相關(guān)。用化學發(fā)光儀測定相對光單位(RLU),計算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA867Hu02 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA867Hu03 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA867Hu04 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
LAA867Hu81 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
LAA867Hu71 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
MAA867Hu21 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA867Hu22 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
SEA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
雜志 | 參考文獻 |
Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women [ScienceDirect: S0765159710000262] |
Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease [Wiley: source] |
34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study [PubMed: 22240497] |
PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo [PubMed: PMC3759413] |
China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats [Source] |
Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. [Pubmed: 23958269] |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Hindawi: 278063] |
Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia [Scirp:Source] |
Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood [Springer:Source] |
Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. [Pubmed:24397392] |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Pubmed:24818163] |
Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes [Pubmed:25034387] |
J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients [PubMed: 26374297] |
Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V [Ebscohost] |
Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome [pmc:PMC4803547] |
Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery [Pubmed:25773594] |
Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … [articles:10.1186] |
Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. [jrnl:1841098] |
Biomarker for diagnosis of moyamoya disease [:] | |
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions [Pubmed: 32859455] |
chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? [] |